drugset / Trial / NCT02499354
Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
Phase 2
Completed
100 enrolled
Auerbach Hematology Oncology Associates P C
AMAG Pharmaceuticals, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to determine the relative effect size of standard IV and oral iron treatment of RLS with Iron deficiency anemia (IDA) and to determine the time course of treatment response.
Timeline
- Start
- 2014-08
- Primary completion
- 2021-09-28
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 325 mg | Oral |
| Comparator | Iron sucrose | Unknown | 510 mg | Intravenous |